China
Africa
Explore chapters and articles related to this topic
Cancer in Multiracial and Multiethnic Populations
Published in Peter G. Shields, Cancer Risk Assessment, 2005
Her-2 gene amplification and protein overexpression is an important predictor of disease progression and has been observed in 20–30% of breast cancers. A polymorphism at codon 655 (Val655Ile) in the transmembrane domain-coding region of the HER2 gene has been identified and may be associated with breast cancer risk in young women under age 45 years. Xie et al. examined the Val(655)Ile polymorphism in a population-based, case–control study of breast cancer in women of Shanghai, China. They observed that women with the Ile/Val or Val/Val genotype had an elevated risk of breast cancer [OR=1.4 (95% CI 1.0–2.0; p = 0.05)] after adjusting for age, education, study period, history of breast fibroadenoma, leisure physical activity, and age at first live birth. The risk was highest in younger women < 45 years (OR = 14.1; 95% CI = 1.8–113.4) than in older women (34). A few studies have examined this potential etiological marker and prognostic predictor of disease in racial/ethnic groups. Ameyaw et al. studied this polymorphism in a multiethnic population of 257 Caucasians, 90 African-American, and 200 African (Ghanaian) healthy blood donors. The Val allele was not detected in the African population. There was no difference in the HER2 allele frequency between African-Americans and Caucasians. The Val allele was detected in 20% of Caucasian alleles, 24% of African-American alleles, and 11% of Chinese alleles. The homozygous Val/Val genotype that is associated with an increased risk of breast cancer was observed in 5.4% Caucasians, 4.4% African-Americans, and 0.3% Chinese (35). In another study of postmenopausal breast cancer patients participating in the Hawaii and Los Angeles Multiethnic Cohort, McKean-Cowdin et al. observed that women with at least one copy of the Valine variant were approximately one-half as likely to have high-stage as low-stage breast cancer. This effect was present across racial/ethnic groups (36).
Feasibility and efficacy of ultrasound-guided high-intensity focused ultrasound of breast fibroadenoma
Published in International Journal of Hyperthermia, 2023
Mengdi Liang, Zhizheng Zhang, Cai Zhang, Rui Chen, Yao Xiao, Zi Li, Tao Li, Yuelin Liu, Lijun Ling, Hui Xie, Lin Chen, Xiaoan Liu, Shui Wang, Tiansong Xia
This prospective study has been registered in Clinical-Trials.gov (ChiCTR2100050068) and approved by the institutional ethics committee of the First Affiliated Hospital with Nanjing Medical University (2020-SR-130). A written informed consent was obtained from each patient. From January 2021 to November 2022, a total of 113 patients diagnosed with breast fibroadenoma by core-needle biopsy in our hospital were recruited and underwent USgHIFU at our department. And the clinical outcome of 85 patients with a follow-up time of more than 3 months was analyzed in this study. The inclusion criterion included the following: (a) patients were older than 18 years; (b) the Breast Imaging Recording and Data System (BI-RADS) score ≤3 by ultrasound and mammography in addition for women older than 35 years; (c) breast fibroadenoma proved by core-needle biopsy; (d) the maximum diameter of lesion was between 5 and 40 mm; and (e) fibroadenomas with a safe acoustic pathway and the focus can reach the target. The exclusion criteria were as follows: (a) pathological diagnosis of breast cancer; (b) BI-RADS score ≥4; (c) pregnant or lactating women; (d) patients with evidence of coagulopathy, chronic liver diseases or renal failure; and (e) patients with breast implants.
Feasibility and efficacy of microwave ablation for treating breast fibroadenoma
Published in International Journal of Hyperthermia, 2021
Gang Liu, Yulu Zhang, Erwei Hu, Xiaoqing Fan, Qiaosheng Wu, Qiuyun Xiong, Zhihua Li
A previous study demonstrated that breast fibroadenoma arise due to proliferation of ductal or lobular tissue, and their treatment is controversial [2]. Small asymptomatic breast lesions generally do not require treatment, and some surgeons tend to favor conservative management of breast fibroadenoma with regular follow-up, which should be accompanied by auxiliary examination (i.e., ultrasound and/or mammography and pathological assessment) every 3-6 monthsin order to dynamically monitor the status of breast lesions [3,4]. However, some patients with large-sized breast fibroadenomas suffering from pain or anxiety are not satisfied with the conservative management approach and seek for treatment [5–7]. Thus, it is necessary to excise part of the breast fibroadenoma according to therapeutic options that depend on different presenting situations [8].
Dosimetric analysis of ultrasound-guided high intensity focused ultrasound ablation for breast fibroadenomas: a retrospective study
Published in International Journal of Hyperthermia, 2022
Cai Zhang, Mengdi Liang, Tiansong Xia, Heng Yin, Hongwei Yang, Zhibiao Wang, Lian Zhang
Fibroadenoma is the most common benign breast tumor in women. Although women of any age can develop this benign tumor, it usually occurs in young women [1,2]. It was reported that about 10% of women have breast fibroadenoma in their lifetime, accounting for 67%−94% of all breast biopsies in women under the age of 20 years [3,4]. Surgical excision is the conventional treatment of choice for fibroadenoma, but patients are worried about the breast scar that may lead to poor cosmetic results. Although vacuum-assisted mammotomy (VAM) was thought to be an alternative treatment in the management of breast fibroadenomas with size smaller than 3 cm, it is still an invasive treatment and the complications of severe bleeding, hematomas, post-operative infections may occur [5].